Findings

What do systematic reviews say?

4,751 questions · 12,775 findings · 807 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3,413 · 26.7%GRADE not reported 709 · 5.5%Very low 3,483 · 27.3%Low 3,165 · 24.8%Moderate 1,628 · 12.7%High 377 · 3%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Hydrocortisone vs placebo

Severity of PTSD symptoms · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propranolol vs placebo

Quality of life at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gabapentin vs placebo

Severity of PTSD symptoms ‐ Clinician‐rated · adults (aged 18 and older) exposed to a traumatic event

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
Very low

Gabapentin vs placebo

Dropouts due to adverse events · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gabapentin vs placebo

PTSD rate at 3 months · adults (aged 18 and older) exposed to a traumatic event

It is very uncertain whether gabapentin changes PTSD rate at 3 months compared with placebo (very low certainty).

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
RR 0.8 [0.18, 3.59]
1 study · 26 participants
Very low

Gabapentin vs placebo

Functional disability at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gabapentin vs placebo

Quality of life at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydrocortisone vs placebo

Dropouts due to adverse events · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydrocortisone vs placebo

PTSD rate at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydrocortisone vs placebo

Functional disability at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydrocortisone vs placebo

Quality of life at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propranolol vs placebo

Severity of PTSD symptoms ‐ Clinician‐rated · adults (aged 18 and older) exposed to a traumatic event

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 86 participants
Very low

Propranolol vs placebo

Dropouts due to adverse events · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propranolol vs placebo

PTSD rate at 3 months · adults (aged 18 and older) exposed to a traumatic event

It is very uncertain whether propranolol changes PTSD rate at 3 months compared with placebo (very low certainty).

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
RR 0.77 [0.31, 1.92]
3 studies · 88 participants
Very low

Propranolol vs placebo

Functional disability at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Any intervention vs artificial tears or saline

Mean number of days from treatment initiation to resolution of symptoms or signs (shorter is favored) · epidemic keratoconjunctivitis

1 finding from 1 review

Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Any intervention vs steroid alone or plus levofloxacin

Resolution of symptoms · epidemic keratoconjunctivitis

1 finding from 1 review

Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Any intervention vs steroid alone or plus levofloxacin

Proportion of participants with resolution of signs within 7 days of treatment (higher is favored) · epidemic keratoconjunctivitis

1 finding from 1 review

Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Any intervention vs steroid alone or plus levofloxacin

Proportion of eyes in which SEI had developed within 21 days of treatment (lower is favored) · epidemic keratoconjunctivitis

It is very uncertain whether any intervention changes proportion of eyes in which SEI had developed within 21 days of… compared with steroid alone or plus levofloxacin (very low certainty).

1 finding from 1 review

Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis 2022 · Cochrane Headline outcomes only
RR 0.08 [0.01, 0.55]
2 studies · 69 participants
Very low

Any intervention vs steroid alone or plus levofloxacin

Proportion of participants in whose eyes SEI had disappeared within 21 days of treatment (higher is favored) · epidemic keratoconjunctivitis

1 finding from 1 review

Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low